Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
126
resultados
Última actualización
19/06/2025 [13:24:00]
Resultados 50 a 75 de 126
Resumen de: CN119613546A
The invention discloses an IL-10 antibody and an application thereof. The anti-human IL-10 monoclonal antibody human IL-10 protein provided by the invention has relatively strong affinity, can be used for detecting the expression of the human IL-10 protein, can also be applied to immunotherapy independently or in combination with other methods, and has diagnosis and treatment values in tumors, inflammatory bowel diseases and rheumatism immune diseases.
Resumen de: US2025084174A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Resumen de: US2025084480A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: CN119587515A
The invention belongs to the field of biological medicines, and particularly relates to application of nordihydroguaiamic acid and derivatives thereof in preparation of products for treating inflammatory bowel diseases. By exogenous supplementation of nordihydroguaiamic acid (NDGA), DSS-induced mouse enteritis is remarkably relieved, survival prognosis of mice is improved, mucosal barrier dysfunction of UC mice is remarkably improved, the number of inflammatory macrophage subgroups is reduced, transcription generation of colon tissue proinflammatory factors and activated cleavage of pyroptosis-related proteins are inhibited, and the application of the NDGA is developed. Good anti-inflammatory effect and intestinal protection effect are achieved. The NDGA is further found to be capable of remarkably improving the mucosal barrier function disorder of the UC mouse, and the NDGA is prompted to have a good intestinal protection effect; the NDGA can inhibit the transcriptional generation of IL-1beta by regulating and controlling the NR4A1-Serpin1 pathway and reduce the co-localization of NR4A1 and NLRP3 in macrophages, which prompts that the NDGA can regulate and control the interaction relationship of NR4A1 and NLRP3 to inhibit inflammation.
Resumen de: WO2024008796A1
The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.
Resumen de: CN119560000A
The invention provides an irritable bowel syndrome intestinal microbial marker, application thereof and a method for constructing a detection model, and belongs to the technical field of medicine and biomedicine. By utilizing the irritable bowel syndrome intestinal microbial marker, the association between the marker level and IBS symptom severity, the life quality of a patient and the treatment effect can be evaluated, and personalized diet, prebiotics, probiotics or antibacterial drugs and other treatment suggestions are provided for the patient according to the specific intestinal microbial marker composition of the patient. According to the invention, the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of IBS are improved, the understanding of IBS is deepened, and the development of microbiomics in clinical application is promoted. The AUC value of the irritable bowel syndrome detection model reaches 0.9931, which shows that the classifier has good performance when distinguishing positive and negative samples.
Resumen de: TW202509234A
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: CN119541878A
The invention provides a training method and system of an inflammatory bowel disease diagnosis and prediction model based on data driving, a storage medium and electronic equipment, and relates to the technical field of model training. According to the method, the BP feedforward neural network is adopted to process and analyze the standard data of each inspection index extracted from the ultrasonic diagnosis report text, so that the rehabilitation cycle of the patient with the inflammatory bowel disease is predicted. Through training and verification, the model shows high accuracy and reliability, and provides a powerful decision support tool for doctors. In addition, the dynamic adjustment and updating capability of the model ensures that the model can adapt to continuously changing clinical data in practical application, and the application value in personalized treatment planning and disease management is further enhanced.
Resumen de: WO2024008796A1
The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.
Resumen de: CN119529078A
本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的活性和灵敏度。
Resumen de: CN119529077A
本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的亲和力或活性。
Resumen de: US2025069692A1
The invention is related to a system for treating irritable bowel syndrome, Crohn's disease, ulcerative colitis (collectively, inflammatory bowel disease, or “IBD”) by determining a number of indicators, including genetic markers, gene expression levels, levels of certain compounds in the gut or feces, hydrogen and/or methane levels, and concentrations of particular bacteria in the gut or feces, and correlating one or more such indicators with symptoms in test subjects with IBD; and correlating diet, drugs, supplements or other therapy, with alleviation of IBD symptoms. The correlations established in the test subjects are confirmed or refuted for individuals suffering IBD, and the treatments established as reducing symptoms are supported through messaging and compliance is verified by monitoring the indicators.
Resumen de: AU2023257366A1
The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.
Resumen de: CN119510374A
The invention relates to a fluorescent array sensor, in particular to a difunctional fluorescent array sensor containing a modified high-molecular polymer, a preparation method of the difunctional fluorescent array sensor and application of the difunctional fluorescent array sensor in bacterial detection and fermentation carbohydrate detection. The array sensor comprises at least two different fluorescent sensing units, each fluorescent sensing unit is a PN-coumarin dye compound formed by covalent interaction of PN and coumarin dye, PN is a nitrophenylboronic acid modified high-molecular polymer PEI, the coumarin dye is 6, 7-diphenyl-1, 3, 4-triazole-3-carboxylic acid, and the coumarin dye is a coumarin dye compound. The compound is selected from the group consisting of 2, 7-dihydroxy-2H-benzopyran-2-one ES or 4-methylesculetin MS. The compound fluorescent array sensor disclosed by the invention can simultaneously realize distinguishing detection of thirteen types of bacteria related to IBS and fourteen FODMAPs, and has the advantages of high sensitivity, short detection time, low cost, good repeatability, high accuracy, no need of professional technicians and the like.
Resumen de: CN119488592A
本申请涉及BAZ2B作为靶点在非酒精性脂肪肝以及肝炎中的应用。更具体的，本申请涉及用于调节BAZ2B表达或活性的药剂，如BAZ2B的下调剂；包含所述调节BAZ2B表达或活性的药剂的组合物；以及调节BAZ2B在细胞中表达水平或活性的方法，例如抑制BAZ2B的表达或活性的方法。本申请还涉及通过调节BAZ2B在细胞中表达水平或活性，从而治疗或改善肝脏疾病的方法，所述肝脏疾病例如包括与脂类代谢相关的疾病、非酒精性脂肪性肝病(nonalcoholic fatty liver disease，NAFLD)、非酒精性脂肪性肝炎(non‑alcoholic steatohepatitis，NASH)和肥胖。
Resumen de: WO2025038942A1
Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.
Resumen de: US2025057842A1
Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.
Resumen de: US2025059605A1
The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.
Resumen de: WO2023201243A1
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Resumen de: CN119487012A
The present disclosure provides a pharmaceutical composition, the pharmaceutical composition comprises a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; the present invention relates to a pharmaceutical composition comprising a dose unit comprising one or more of Compound (A), Compound (B), Compound (C), Compound (D), Compound (E), Compound (F), Compound (G), Compound (H), Compound (J), Compound (K), Compound (L), Compound (M), Compound (N), Compound (O), Compound (P), or Compound (Q) or a pharmaceutical composition described herein, a method of treating inflammatory bowel disease in a subject in need thereof, and a pharmaceutical composition comprising one or more of Compound (A), Compound (B), Compound (C), Compound (D), Compound (E), Compound (F), Compound (G), Compound (H), Compound (J), Compound (K), Compound (L), Compound (M), Compound (N), Compound (O), Compound (P), or Compound (Q). Or methods of modulating an inflammatory bowel disease marker in a subject in need thereof. # imgabs0 # imgabs1 #
Resumen de: CN119454756A
The invention provides an adipose-derived stem cell exosome and application of the adipose-derived stem cell exosome in treatment of colitis and mesentery. It is verified for the first time that the adipose-derived stem cell exosome CrF-exo from crawling adipose tissue regulates the lymphatic endothelial cell function and promotes lymphatic drainage in colon and mesentery and finally relieves inflammation of the colon and mesentery, and it is found through verification that CrF-exo-miR-132-3p promotes the lymphatic endothelial cell function and CCL21 secretion through an RASA1/ERK1/2 axis; the miR-132-3p is highly expressed in CrF and inflammatory intestines of a CD patient along with increase of lymphatic vessel density; the expression of miR-132-3p in serum of a patient is also increased and is negatively correlated with an inflammation biomarker. The research result provides a new insight for the effect of the mesenteric lymphatic function in CD progress and a potential treatment method for targeting lymphatic vessels to treat CD mesenteric and intestinal lesions.
Resumen de: CN119464306A
Provided is a cinnamyl aldehyde-loaded solid-liquid biphasic artificial cell (SL-BACs) which has a solid-phase protective film and a liquid multicore, and which is efficiently and stably produced using a microfluidic T-type chip. The SL-BACs can provide multi-aspect treatment assistance for colitis induced by salmonella typhimurium. Firstly, an aptamer in a liquid multinuclear shows accurate targeting at an infected part; secondly, the encapsulation efficiency of the SL-BACs on the cinnamyl aldehyde is relatively high, and is about 82.9 percent; thirdly, the intestinal retention time of the SL-BACs is prolonged to 15 h through the membrane structure; in addition, the SL-BACs show pH responsiveness, liquid multi-core antibiosis is controlled to be released, and the sterilization rate is 95.28%. The SL-BACs can also reduce the secretion of proinflammatory cytokines, optimize the composition of intestinal microbiota and maintain the steady state of the intestinal tract. In a word, the SL-BACs provide necessary conditions for modularizing the artificial cells into an oral system for targeted therapy.
Resumen de: CN119478498A
A method for automatically judging which of three common diseases, namely hepatocellular carcinoma (HCC), intrahepatic cholangiocellular carcinoma (ICC) and fatty liver (FAT), the liver belongs to is based on a neural network introduced with r-IBS, and the method comprises the following steps: firstly, constructing a training classifier based on r-IBS, and judging which of the diseases belongs to each liver CT by using the classifier; and collecting CT images of the liver, carrying out image processing by using a snake model, inputting the images into the trained classification neural network model, and outputting a classification result of the diseases from the neural network.
Nº publicación: CN119438591A 14/02/2025
Solicitante:
中国人民解放军海军军医大学第一附属医院
Resumen de: CN119438591A
本申请提供了一种蛋白标志物在制备检测炎症性肠病的检测产品中的应用。其中，蛋白标志物选自如下任意一个或多个蛋白分子：MRPL43、ECHS1、TLN2、ENO3、NCSTN、CTSH、CKMT1、TUBA4A、DYNC1H1、PDLIM3、GLB1及PMPCA。本申请通过实验证明了上述12个蛋白的瓜氨酸水平与炎症性肠病高度关联，因而可将其中的一个或多个作为蛋白标志物来制备检测炎症性肠病的检测产品(比如检测或诊断试剂盒等)。基于上述蛋白标志物的检测产品有助于实现尽早检测和无创检测，快捷、方便、准确。
BOPI
Sede Electrónica
